Pharmaceutical composition containing palonosetron

A pharmaceutical package, comprising:

• a pharmaceutically acceptable container, and
• a pharmaceutical composition comprising:
• palonosetron or pharmaceutically acceptable salts thereof in the container as an active ingredient at a concentration of 0.01 to 0.5 mg/ml;
• a pharmaceutically acceptable aqueous carrier;
• a buffering agent, an isotonic agent, or a mixture thereof,
• wherein the pharmaceutically acceptable container is a transparent borosilicate glass container, and the glass is a low-expansion borosilicate glass, satisfying ASTM type 1, class A, USP type 1 Powdered Glass, USP Arsenic, EP type 1 Glass Grains (Test B) and EP Arsenic conditions, and
• wherein the pH of the pharmaceutical composition is 4 to 6,
• wherein the pharmaceutical composition is free of EDTA or a salt thereof,
• wherein a total content of heavy metals is maintained to be equal to or less than 50 ppm during a storage period, and
• wherein the pharmaceutical composition has storage stability of maintaining the content of palonosetron or a pharmaceutically acceptable salt thereof at 95% by weight to 100% by weight based on the initial content thereof when the pharmaceutical composition is stored at 25 ° C. for 24 months.